Date: 2016-04-20
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: Immune Design (USA - MA)
Product: ZVex™ platform
Action
mechanism:
- immunotherapy product. ZVex™ is a discovery platform that uses a first-in-class vector to generate product candidates designed to create cytotoxic T lymphocytes in vivo.
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On April 20, 2016, Immune Design announced the presentation of new preclinical data demonstrating broad anti-tumor activity of its ZVex™ platform and further evidence of the anti-tumor activity of G100, both via intratumoral administration. Results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. The company presented data describing the intratumoral administration of a ZVex Interleukin-12 (IL-12) vector to generate localized, intratumoral expression of IL-12. Results presented demonstrate strong local and systemic anti-tumor efficacy of the ZVex/IL-12 across multiple pre-clinical tumor models, including synergy when co-administrated with anti-CTLA-4 and GLA, Immune Design's synthetic TLR4 agonist, Glucopyranosyl Lipid A, the core of Immune Design's GLAAS™ platform.
Is
general: Yes
